Grand Pharmaceutical Advances Sepsis Treatment with Successful Phase II Study

Grand Pharmaceutical Group Limited ( (HK:0512) ) has provided an update.

Grand Pharmaceutical Group Limited announced that its Phase II clinical study of the innovative drug STC3141 for sepsis treatment in China has successfully reached its clinical endpoint. This development marks a significant advancement in sepsis treatment by targeting immune homeostasis, addressing a major clinical gap. The study demonstrated the drug’s effectiveness and safety, with significant improvements in patient outcomes compared to the placebo. The company plans to seek breakthrough therapeutic drug designation from Chinese regulators, highlighting its strong R&D capabilities and the urgent need for targeted sepsis treatments.

More about Grand Pharmaceutical Group Limited

Grand Pharmaceutical Group Limited operates in the pharmaceutical industry, focusing on the research and development of innovative drugs. Its primary products include treatments for severe and critical diseases, with a market focus on addressing unmet clinical needs globally.

YTD Price Performance: 29.19%

Average Trading Volume: 9,729,246

Technical Sentiment Signal: Sell

Current Market Cap: HK$21.05B

For detailed information about 0512 stock, go to TipRanks’ Stock Analysis page.